Showing 3081-3090 of 18629 results for "".
RENEU (A Study to Evaluate the Safety, Effectiveness, and Tolerability of Gomekli in Children Aged ≥2 Years and Adults with an Inoperable NF1-PN; NCT03962543)
https://reachmd.com/programs/practical-neurology/trials-in-2/35433/Christopher Moertel, MD, Medical Director of the Pediatric Neuro-Oncology and Neurofibromatosis Programs at the University of Minnesota provides an overview of the ReNeu clinical trial which evaluated the safety, effectiveness, and tolerability of Gomekli in children aged ≥2 years and adults.Isolated Distal DVT in Cancer Cells for Longer DOAC Treatment
https://reachmd.com/cme/pace-cme/isolated-distal-dvt-cancer-cells-longer-doac-treatment/16003/Here's a recap of the ONCO DVT trial, as presented at the 2023 ESC Congress.Boston Legal's Christian Clemenson on Aspergers II
https://reachmd.com/programs/clinicians-roundtable/boston-legals-christian-clemenson-on-aspergers-ii/1977/Can an actor teach us how to better undertand our patients? Christian Clemenson, who plays Jerry "Hands" Espenson on Boston Legal discusses his role as a chacter with Aspergers Syndrome with host Dr. Bill Rutenberg.Impact of Early Thimerosal Exposure on Children
https://reachmd.com/programs/clinicians-roundtable/impact-of-early-thimerosal-exposure-on-children/1698/Does early thimerosal exposure have negative psychological outcomes? Dr. Bill Rutenberg talks with William Thompson, the Lead Author of a recent NEJM published study, Early Thimerosal Exposure and Neuropsychological Outcomes at 7 to 10 Years.The Dose Matters: Optimizing Statin Intensity in ASCVD Management
https://reachmd.com/programs/cme/the-dose-matters-optimizing-statin-intensity-in-ascvd-management/35816/Join our experts for case-based episodes that focus on bridging the gap between rural health and cardiovascular disease. Experts will explore ASCVD prevention and treatment by reviewing patient risk factors and determining ASCVD risk reduction strategies. This activity is designed to empower healthcEvaluating Brogidirsen for Exon 44 Skipping in DMD: Early-Phase Insights
https://reachmd.com/programs/clinicians-roundtable/evaluating-brogidirsen-for-exon-44-skipping-in-dmd-early-phase-insights/35682/As new exon-skipping therapies for Duchenne muscular dystrophy (DMD) emerge, a novel agent—brogidirsen—has shown encouraging early results in targeting exon 44. Read about findings from a recent phase 1/2 trial that explored the safety and biological activity of brogidirsen and learn how these resulUnderstanding Pediatric Eye Disorders: Key Insights from AAP 2025
https://reachmd.com/programs/clinicians-roundtable/pediatric-eye-disorders-key-insights-from-aap-2025/36566/Pediatricians are often the first to encounter eye conditions that can range from common to life-threatening. Hear from Dr. Laura Enyedi as she shares highlights from her presentation on diagnosing childhood ocular disorders from the 2025 American Academy of Pediatrics (AAP) National ConferenA Journey Right from Residency: Insights on Locum Tenens
https://reachmd.com/programs/locumtenens/a-journey-right-from-residency-insights-on-locum-tenens/13568/From first assignments to lessons learned—what do residents need to know about locum tenens?A Look at HIV & Its Link to Cancer
https://reachmd.com/programs/project-oncology/a-look-at-hiv-its-link-to-cancer/13637/Men living with HIV are more likely to develop cancer. What do we need to know about this link?Exploring Epilepsy: Does Pregnancy Increase the Risk of Seizures?
https://reachmd.com/programs/neurofrontiers/exploring-epilepsy-does-pregnancy-increase-the-risk-of-seizures/12471/How can neurology specialists prevent seizures in pregnant women with epilepsy?